Presentation Title: AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in vivohttps://www.abstractsonline.com/pp8/#!/10517/presentation/17070 Presentation
Aurigene will be attending 2017 MassBio Annual Meeting, scheduled to be held on March 30-31, 2017 at Boston, Massachusetts. For more details about the conference, please click here
Aurigene will be attending 2017 American Academy of Dermatology Annual Meeting, scheduled to be held on March 03-07, 2017 at Orlando, Florida. For more details about the conference, please click
Advances in New Drug Discovery & Development Feb 2-4, 2017, Ahmedabad, India Scientists and R & D professionals from across the globe will be at arms reach when they gather
J.P Morgan Annual Healthcare Conference continues to be one of the life science industry’s largest conferences of the year. It brings thousands of investors and executives from around the world
